241 related articles for article (PubMed ID: 31669227)
1. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients.
Franken A; Honisch E; Reinhardt F; Meier-Stiegen F; Yang L; Jaschinski S; Esposito I; Alberter B; Polzer B; Huebner H; Fasching PA; Pancholi S; Martin LA; Ruckhaeberle E; Schochter F; Tzschaschel M; Hartkopf AD; Mueller V; Niederacher D; Fehm T; Neubauer H
J Mol Diagn; 2020 Jan; 22(1):111-121. PubMed ID: 31669227
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
[TBL] [Abstract][Full Text] [Related]
3. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
Yanagawa T; Kagara N; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Jun; 163(2):231-240. PubMed ID: 28283903
[TBL] [Abstract][Full Text] [Related]
4. Detection of Activating Estrogen Receptor Gene (
Paolillo C; Mu Z; Rossi G; Schiewer MJ; Nguyen T; Austin L; Capoluongo E; Knudsen K; Cristofanilli M; Fortina P
Clin Cancer Res; 2017 Oct; 23(20):6086-6093. PubMed ID: 28679775
[No Abstract] [Full Text] [Related]
5.
Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
[No Abstract] [Full Text] [Related]
6. Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
Sefrioui D; Perdrix A; Sarafan-Vasseur N; Dolfus C; Dujon A; Picquenot JM; Delacour J; Cornic M; Bohers E; Leheurteur M; Rigal O; Tennevet I; Thery JC; Alexandru C; Guillemet C; Moldovan C; Veyret C; Frebourg T; Di Fiore F; Clatot F
Int J Cancer; 2015 Nov; 137(10):2513-9. PubMed ID: 25994408
[TBL] [Abstract][Full Text] [Related]
7. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO; Spring LM; Bardia A; Wander SA
Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
[TBL] [Abstract][Full Text] [Related]
8. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
Clatot F; Perdrix A; Beaussire L; Lequesne J; Lévy C; Emile G; Bubenheim M; Lacaille S; Calbrix C; Augusto L; Guillemet C; Alexandru C; Fontanilles M; Sefrioui D; Burel L; Guénot S; Richard D; Sarafan-Vasseur N; Di Fiore F
Breast Cancer Res; 2020 May; 22(1):56. PubMed ID: 32466779
[TBL] [Abstract][Full Text] [Related]
9. [Clinical relevance of ESR1 circulating mutations detection in hormone receptor positive metastatic breast cancer].
Clatot F; Perdrix A; Sefrioui D; Sarafan-Vasseur N; Di Fiore F
Bull Cancer; 2018 Jan; 105(1):46-54. PubMed ID: 29032804
[TBL] [Abstract][Full Text] [Related]
10. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
11. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
Bardia A; Iafrate JA; Sundaresan T; Younger J; Nardi V
Oncologist; 2016 Sep; 21(9):1035-40. PubMed ID: 27551012
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
Guttery DS; Page K; Hills A; Woodley L; Marchese SD; Rghebi B; Hastings RK; Luo J; Pringle JH; Stebbing J; Coombes RC; Ali S; Shaw JA
Clin Chem; 2015 Jul; 61(7):974-82. PubMed ID: 25979954
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
14. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Chung JH; Pavlick D; Hartmaier R; Schrock AB; Young L; Forcier B; Ye P; Levin MK; Goldberg M; Burris H; Gay LM; Hoffman AD; Stephens PJ; Frampton GM; Lipson DM; Nguyen DM; Ganesan S; Park BH; Vahdat LT; Leyland-Jones B; Mughal TI; Pusztai L; O'Shaughnessy J; Miller VA; Ross JS; Ali SM
Ann Oncol; 2017 Nov; 28(11):2866-2873. PubMed ID: 28945887
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
Sundaresan TK; Dubash TD; Zheng Z; Bardia A; Wittner BS; Aceto N; Silva EJ; Fox DB; Liebers M; Kapur R; Iafrate J; Toner M; Maheswaran S; Haber DA
Breast Cancer Res Treat; 2021 Jul; 188(1):43-52. PubMed ID: 34101078
[TBL] [Abstract][Full Text] [Related]
16. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
Fribbens C; Garcia Murillas I; Beaney M; Hrebien S; O'Leary B; Kilburn L; Howarth K; Epstein M; Green E; Rosenfeld N; Ring A; Johnston S; Turner N
Ann Oncol; 2018 Jan; 29(1):145-153. PubMed ID: 29045530
[TBL] [Abstract][Full Text] [Related]
17. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
18. Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.
Leal MF; Haynes BP; Schuster E; Yeo B; Afentakis M; Zabaglo L; Martins V; Buus R; Dodson A; Cheang MCU; Smith IE; Martin LA; Dowsett M
Clin Cancer Res; 2019 Dec; 25(24):7485-7496. PubMed ID: 31548345
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients.
Babayan A; Hannemann J; Spötter J; Müller V; Pantel K; Joosse SA
PLoS One; 2013; 8(9):e75038. PubMed ID: 24058649
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
